Peter F. Rebeiro, PhD, MHS On behalf of: Carina Cesar, Bryan E. Shepherd, Raquel B. De Boni, Claudia Cortés, Fernanda Rodriguez, Pablo Belaunzarán-Zamudio,

Slides:

Advertisements

Similar presentations

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention June 30-July 3, 2013; Kuala Lumpur, Malaysia Dolutegravir (DTG) is Superior to Raltegravir.

Advertisements

Estimating the number of Kentuckians living with HIV disease with unmet needs for HIV-related primary care in calendar year 2010  Reducing new HIV infections.

Cascade The Continuum of HIV Care Florida, 2012 Lorene Maddox, MPH Karalee Poschman, MPH Living data through 2012, as of 06/30/2013.

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

IMPLEMENTATION OF THE BRAZILIAN HIV/AIDS ANTIRETROVIRAL PROGRAM AT A PUBLIC HEALTH POST: ADHERENCE TO PRESCRIBING GUIDELINES AND TREATMENT CONTINUITY Carmody.

SPECTRUM OF CARE ENGAGEMENT-ARIZONA PREVALENT CASES 2012 Note: HIV infected is derived using CDC’s national infection estimation guidelines.

Cascade The Continuum of HIV Care Florida, 2013 Lorene Maddox, MPH Karalee Poschman, MPH Living data through 2013, as of 06/30/2014.

HIV Care Continuum, Men Who Have Sex with Men Only (MSMO) and Men Who Have Sex with Men and Women (MSMW), Georgia, 2012.

Late HIV Diagnoses, Georgia,

Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.

HIV Care Continuum for the United States and Puerto Rico National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.

HIV/AIDS Epidemiology Update February 2009 Dr Nigel Dickson Director, AIDS Epidemiology Group Department of Preventive and Social Medicine University of.

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.

Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.

Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.

Ways to Analyze Data to Monitor Progress on the National HIV/AIDS Strategy Angelique Griffin, MS DC Department of Health HIV/AIDS, Hepatitis, STD and TB.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

HIV Care Continuum, District 8- 2 Southwest (Albany), Georgia, 2012.

Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.

The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.

Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.

Washington D.C., USA, July 2012www.aids2012.org Equal behaviors, unequal risks: The role of partner transmission potential in racial HIV disparities.

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

HIV Care Continuum, Georgia, United States, 2011 Presented to American Public Health Association, Annual Meeting Presented by Deepali Rane, MBBS, MPH,

Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,

David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.

Engagement in the HIV care cascade among transgender women enrolled in a public HIV clinic in Buenos Aires, Argentina, M.E. Socías 1,2, O. Sued.

Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.

Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.

HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.

HIV Care Continuum, District 10 Northeast (Athens), Georgia, 2012.

Monitoring Indicators of the National HIV/AIDS Strategy Using Data for Public Health Action Irene Hall, PhD, FACE HIV Incidence and Case Surveillance Branch.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.

HIV Care Continuum Persons Living With HIV, Georgia, 2012.

Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.

Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.

The immune reconstitution inflammatory syndrome (IRIS) in HIV infected patients comprises a group of inflammatory symptoms associated with the appearance.

Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.

The Continuum of HIV Care Florida, 2014 The Continuum of HIV Care Florida, 2014 Lorene Maddox, MPH Karalee Poschman, MPH Living data through 2014, as of.

Mean HIV viral load among resident cases and undiagnosed in Oregon Jeff Capizzi, Epidemiologist Sean Schafer, HIV/STD/TB Medical Epidemiologist Lea Bush,

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent

Viral load distribution 2012 among persons living with HIV and persons newly diagnosed Georgia, 2011.

HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.

Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.

Mortality during the first year of HAART in HIV-1-infected patients in 7 countries from Latin America and the Caribbean Suely H. Tuboi, MD, PhD On behalf.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Oral Abstract WEAB0101 Trends and predictors of non-communicable disease multi-morbidity among HIV-infected adults initiating ART in Brazil,

AIDS-Defining cancers (n=331) Non-AIDS-Defining cancers (n=75)

BACKGROUND Cancer in Latin American and Caribbean HIV+ populations has not been studied comprehensively. CCASAnet includes sites from Argentina, Brazil,

Earlier treatment and lower mortality in infants Initiating ART at

Viral Suppression at the First Integrated Methadone and Antiretroviral Therapy Program for People who Inject Drugs in sub-Saharan Africa Dar es Salaam,

No conflicts of interest to declare.

Melanie L. Fritza Ronald J. Lubelchek, MD a, b, c*

Conclusions & Implications

HIV Care Continuum in Manhattan

Patients w/AIDS-defining illness

San Francisco Department of Public Health

Dr. Velephi Okello, Principal Investigator, MaxART Trial

AIDS-Defining cancers (n=331) Non-AIDS-Defining cancers (n=75)

BACKGROUND Cancer in Latin American and Caribbean HIV+ populations has not been studied comprehensively. CCASAnet includes sites from Argentina, Brazil,

Conflicting of interest disclosure: None

Andreas D. Haas, PhD Postdoctoral fellow, ICAP at Columbia University

Update on global progress in ART

Public Health Implications

Presentation transcript:

Peter F. Rebeiro, PhD, MHS On behalf of: Carina Cesar, Bryan E. Shepherd, Raquel B. De Boni, Claudia Cortés, Fernanda Rodriguez, Pablo Belaunzarán-Zamudio, Jean W. Pape, Denis Padgett, Daniel Hoces, Catherine C. McGowan, and Pedro Cahn of the Caribbean, Central and South America network for HIV epidemiology (CCASAnet) Assessing the HIV Care Continuum in CCASAnet: progress in clinical retention, ART use, and viral suppression July 22, 2015

1. Retention: ≥2 HIV primary care encounters per year, >90 days apart (US Institute of Medicine) 2. ART use: ART during the year, among those with ≥1 HIV primary care visit during the year (US Department of Health and Human Services) 3. Viral suppression: HIV-1 RNA <200 copies/mL at the last measurement in the year, among those with ≥1 HIV primary care visit during the year (US Department of Health and Human Services) Adapted from Ford MA, and Spicer CM. Monitoring HIV care in the United States: indicators and data systems. National Academies Press; 2012.

CD4 and VL used as proxies for clinic visit in Argentina and Peru Haiti excluded from ART outcome, ART use was cohort inclusion criterion Haiti excluded from viral suppression outcome, VL monitoring not available Modified Poisson regression with Generalized Estimating Equations (GEE) to account for multiple outcomes per individual Restricted cubic splines to allow non-linear relationships between age, year of assessment, and outcomes

Characteristic Total for Retention a Not Retained a Retained a p-value* (N=18,799) Total89,55723,86965,688 Age (Years) 36.1 (30.0, 43.0) 35.2 (29.3, 41.7) 36.4 (30.3, 43.5) 0.21 Sex Male56,72515,321 (27.0)41,404 (73.0)Ref. Female32,8328,548 (26.0)24,284 (74.0)0.24 HIV Risk Factor MSM25,5537,515 (29.4)18,038 (70.6)Ref. IDU1, (52.7)735 (47.3)<0.01 Hetero28,9389,454 (32.7)19,484 (67.3)<0.01 Other/Unk.33,5116,080 (18.1)27,431 (81.9)<0.01 Country Argentina d 18,8787,598 (40.2)11,280 (59.8)Ref. Brazil17,3994,922 (28.3)12,477 (71.7)<0.01 Chile11,9382,723 (22.8)9,215 (77.2)<0.01 Haiti e 4,2791,027 (24.0)3,252 (76.0)<0.01 Honduras23,0743,438 (14.9)19,636 (85.1)<0.01 Mexico3, (15.1)3,340 (84.9)<0.01 Peru d 10,0563,568 (35.5)6,488 (64.5)<0.01 Individual Years in Care7 (4, 9) <0.01 Characteristics of individuals in CCASAnet contributing to analyses of HIV Care Continuum indicators from 2003 through 2012 a.US Institute of Medicine retention indicator: individuals with ≥2 HIV primary care encounters per year, >90 days apart d. Argentina and Peru used laboratory measures (CD4+ counts and HIV-1 RNA measures) as proxies for HIV primary care visits when determining retention status

Characteristic Total for ART b Not on ART b On ART b p-value* (N=14,380) Total68,87711,56557,312 Age (Years) 35 (29.1, 41.9) 32.5 (27.1, 39.3) 35.5 (29.6, 42.4) <0.01 Sex Male49,1018,119 (16.5)40,982 (83.5)Ref. Female19,7763,446 (17.4)16,330 (82.6)0.7 HIV Risk Factor MSM27,3045,079 (18.6)22,225 (81.4)Ref. IDU1, (15.1)1,141 (84.9)0.25 Hetero29,7454,800 (16.1)24,945 (83.9)0.17 Other/Unk.10,4841,483 (14.2)9,001 (85.9)<0.01 Country Argentina d 18,7213,549 (19.0) (81.0)Ref. Brazil18,3183,253 (17.8)15,065 (82.2)0.34 Chile12,5482,282 (18.2)10,266 (81.8)0.8 Haiti e N/A Honduras3, (7.8)2,778 (92.2)<0.01 Mexico4, (9.7)4,252 (90.3)<0.01 Peru d 11,5671,788 (15.5)9,779 (84.5)<0.01 Individual Years in Care8 (5, 10)6 (3, 8)8 (5, 10)<0.01 Characteristics of individuals in CCASAnet contributing to analyses of HIV Care Continuum indicators from 2003 through 2012 b. cART was defined as regimens of ≥3 active antiretroviral agents (including triple-nucleoside regimens); US Department of Health and Human Services ART indicator: number of individuals prescribed ART during the year, among those with ≥1 HIV primary care visit during the year e. Haiti did not contribute to the assessment of ART use due to receipt of ART being an inclusion criterion of the clinical cohort; Haiti did not contribute to the assessment of viral suppression due to a lack of universal HIV-1 RNA testing within the clinical cohort

Characteristic Total for Viral Suppression c No Viral Suppression c Viral Suppression c p-value* (N=13,330) Total60,64017,70842,932 Age (Years) 35.3 (29.3, 42.1) 33.4 (27.6, 40.2) 35.9 (30.0, 42.9) <0.01 Sex Male43,47412,357 (28.4)31,117 (71.6)Ref. Female17,1665,351 (31.2)11,815 (68.8)0.11 HIV Risk Factor MSM24,0266,970 (29.0)17,056 (71.0)Ref. IDU1, (28.6)851 (71.5)0.96 Hetero25,9657,988 (30.8)17,977 (69.2)0.56 Other/Unk.9,4582,410 (25.5)7,048 (74.5)<0.01 Country Argentina d 17,2825,127 (29.7)12,155 (70.3)Ref. Brazil17,1675,215 (30.4)11,952 (69.6)0.78 Chile10,1162,618 (25.9)7,498 (74.1)0.2 Haiti e N/A Honduras1, (12.6)1,157 (87.4)<0.01 Mexico4, (17.1)3,778 (82.9)<0.01 Peru d 10,1953,803 (37.3)6,392 (62.7)<0.01 Individual Years in Care7 (5, 10)6 (4, 9)8 (5, 10)<0.01 Characteristics of individuals in CCASAnet contributing to analyses of HIV Care Continuum indicators from 2003 through 2012 c. US Department of Health and Human Services viral suppression indicator: individuals with plasma HIV-1 RNA <200 copies/mL at the last measurement in the year, among those with ≥1 HIV primary care visit during the year e. Haiti did not contribute to the assessment of cART use due to receipt of cART being an inclusion criterion of the clinical cohort; Haiti did not contribute to the assessment of viral suppression due to a lack of universal HIV-1 RNA testing within the clinical cohort

Characteristic Adjusted* RR (95% CI): Retention a Adjusted* RR (95% CI): ART use b Adjusted* RR (95% CI): Viral Suppression c Age (Years) d (0.99,1.09) 0.83 (0.78,0.87) 0.79 (0.75,0.84) (0.98,1.03) 0.94 (0.91,0.98) 0.93 (0.90,0.97) 40 Ref (1.00,1.03) 1.03 (1.01,1.05) 1.04 (1.02,1.06) (0.98,1.08) 1.05 (0.99,1.12) 1.09 (1.03,1.15) Sex Male Ref. Female 0.97 (0.94,0.99) 0.97 (0.93,1.00)0.97 (0.94,1.01) HIV Risk Factor MSM Ref. IDU 0.83 (0.74,0.93) 1.09 (0.98,1.20)1.03 (0.93,1.15) Hetero 1.00 (0.97,1.04) 1.04 (1.01,1.08) 1.01 (0.97,1.05) Other/Unk (0.93,1.02)1.05 (1.00,1.10)1.03 (0.97,1.08) Years in Care 1.02 (1.02,1.02) 1.05 (1.04,1.05) 1.06 (1.06,1.07) Modeled relationships between characteristics of CCASAnet patients and HIV Care Continuum indicators from 2003 through 2012, with 95% Confidence Intervals (95% CI) Bold estimates are statistically significant, p<0.05 *Fully adjusted models include all terms in table, as well as cohort site and calendar time (modeled with a restricted cubic spline with 4 knots)

Limitations: Results within CCASAnet may not be generalizable to HIV population not successfully linked/engaged in care in these countries Additional research is needed to identify social/contextual/economic impediments to achieving positive Care Continuum outcomes, and their causes, in these settings

Conclusions: HIV Care Continuum outcomes have improved over time in this cohort Efforts to improve retention should focus on females and IDUs Efforts to improve ART use should focus on MSM Efforts to improve ART use and viral suppression should focus on younger individuals

Hospital Fernandez and Centro Médico Huésped, Buenos Aires, Argentina Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil Fundación Arriarán, Santiago, Chile Le Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México Instituto de Medicina Tropical Alexander von Humboldt, Lima, Perú CCASAnet Data Coordinating Center, Vanderbilt University School of Medicine, Nashville, TN, USA CCASAnet patients, clinicians, data managers, and investigators Grant U01-AI from the National Institutes of Health, USA

Questions? Thank you!